Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MDVN > SEC Filings for MDVN > Form 8-K on 1-Nov-2012All Recent SEC Filings

Show all filings for MEDIVATION, INC.

Form 8-K for MEDIVATION, INC.


1-Nov-2012

Other Events


Item 8.01 Other Events.

On November 1, 2012 in Tokyo, Japan (October 31, 2012 in San Francisco, CA), Medivation, Inc.'s alliance partner, Astellas Pharma Inc., reported its financial results for its second fiscal quarter ended September 30, 2012. Astellas reported, among other things, that net quarterly sales of XTANDIŽ (enzalutamide) capsules in the U.S., representing U.S. XTANDI sales during the 12-business-day period beginning September 13, 2012, when XTANDI first became available for shipment, were approximately $14 million. In accordance with Tokyo Stock Exchange rules, Astellas also provided guidance on anticipated net sales of XTANDI in the U.S. for Astellas' fiscal year ending March 31, 2013, which guidance was approximately $100 million. Astellas' guidance with respect to future net sales of XTANDI is a forward-looking statement that involves a number of risks and uncertainties, many of which are outside of Astellas' control, including the degree of market acceptance of XTANDI, that could cause actual results to differ materially from projected results.

Medivation is providing this information, which is taken directly from Astellas' public announcement, solely for the purpose of providing all of Medivation's investors with equal access to this third-party information. By providing this information from Astellas, Medivation does not in any way endorse or adopt these numbers or projections. Medivation is not providing any guidance regarding future sales of XTANDI and makes no comment regarding Astellas' guidance with respect to future net sales of XTANDI.

As previously announced, Medivation plans to report its own financial results for the quarter ended September 30, 2012 on November 9, 2012.


  Add MDVN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MDVN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.